Stock Groups

Pfizer begins study of mRNA flu vaccine By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO. A vial with a syringe is seen behind a Pfizer logo. Illustration taken Jan 11, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) -Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech.

This early-stage study, which was conducted in the United States will evaluate the vaccine among healthy adults aged 65 to 85.

“The COVID-19 Pandemic gave us the opportunity to exploit the vast scientific opportunities of mRNA. Influenza remains an area where we see a need for vaccines,” said Kathrin Jansen, head of vaccine research and development at Pfizer (NYSE:).

This study will compare the vaccine’s safety to that of another FDA-approved flu vaccine.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs include futures, stocks, indexes and Forex. Prices are provided not by the exchanges. They are made by market makers. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]